Superlatus, Inc. (“Superlatus”), a U.S.-based holding company of
food products and distribution capabilities
, has
signed a binding letter of intent (the “LOI”) to be acquired by
TRxADE HEALTH, Inc. (NASDAQ:MEDS) (“TRxADE”), a pharmaceutical
exchange platform provider (the “Merger”).
Upon closing of the Merger, shareholders of
Superlatus will receive 30,821,918 shares of MEDS, valued at $7.30
per share, and comprised of (i) common shares in an amount
representing 19.99% of the total issued and outstanding stock of
MEDS after Closing, and (ii) the remainder in shares of a new class
of MEDS non-voting preferred stock, in each case multiplied by such
shareholder’s pro rata percentage ownership.
The Merger is subject to customary closing
conditions including completion of due diligence, delivery of
audited financials, approval of a continued listing by Nasdaq and
completion of any regulatory approvals.
Other significant closing conditions include the
acquisition by Superlatus of Sapientia, Inc. (“Sapientia”), a food
tech business led by Dr. Eugenio Bortone, one of the world’s most
preeminent food scientists, extrusion processing experts, and
inventor of Frito-Lay’s Twisted Cheetos. Sapientia has created and
filed four foundational patents revolving around the “protein curl”
and crispy puff style snack. By focusing on the texture and crunch,
Sapientia’s disruptive patents solve one of the major problems
large-scale snack-food companies have struggled with for years; the
utility of the snack; including texture, flavor, and offering a
guilt free, not fried, natural and healthy alternative to many
other snack food products on the market today. A related closing
condition to the Merger is completion of a valuation report for
Superlatus following the acquisition of Sapientia reflecting a
value of at least $225,000,000,
After the Merger, TRxADE will pivot its business
focus and branding to become an industry-leading processing and
forming technologies company that creates the latest generation of
delicious, high nutrition, high taste and texture plant-based foods
and snacks. Their other planned products include plant-based meats
and plant-based meat snacks, plant-based dairy milks and yogurts,
and pulse-based “puffed/twisted” snack foods, prioritizing high
protein, low fat, nutritious products with delicious taste and
texture, for both humans and pets. TRxADE plans to divest its
existing operating business and assets shortly after the
Merger.
“This announcement is a significant milestone
for TRxADE shareholders, and we believe that the combined entities
will unlock significant value and synergies to be a significant
player in the competitive food and snack marketplace,” said Suren
Ajjarapu. Founder, Chairmen/CEO and Director of TRxADE. “We believe
this strategic transaction that restructures the business to focus
on the combined strengths of each organization will provide a
competitive advantage in the industry and allow us to gain market
share through quality products, customer adoption, and through
accretive acquisitions that will create substantial value and
returns to our shareholders.”
Superlatus’ interim CEO, Tim Alford, commented:
“Through this transaction, we believe we will form a company with
an exciting growth strategy.” He continued, “Given the extensive
pipeline of potential Food Tech acquisitions that will be enabled
by the Nasdaq listing, we anticipate it will bring many benefits to
all stakeholders.”
The Board of Directors of both companies have
unanimously approved the LOI, and the Merger would be expected to
close in late third quarter or early fourth quarter of 2023.
About Superlatus,
Inc.
Superlatus is a diversified food technology
company with distribution capabilities. We scale food innovation
and transformational change to our food systems to optimize food
security and population health via innovative CPG products,
agritech, foodtech, plant-based proteins and alt-proteins. We
provide industry-leading processing and forming technologies that
create high nutrition, high taste, and textured foods. Our
management team consists of world-class food executives with an
unparalleled understanding of technology and taste. For more
information on Superlatus, please visit Superlatus’ website at
https://www.superlatusfoods.com.
About TRxADE HEALTH,
INC.
TRxADE HEALTH (NASDAQ: MEDS) is a health
services IT company focused on digitalizing the retail pharmacy
experience by optimizing drug procurement, the prescription journey
and patient engagement in the U.S. The Company operates
the TRxADE drug procurement marketplace serving
approximately 14,500+ members nationwide, fostering price
transparency and under the Bonum Health brand, offering patient
centric telehealth services. For more information on TRxADE
HEALTH, please visit the Company’s IR website
at investors.trxadegroup.com.
Forward-Looking Statements
This press release contains certain statements
that may be deemed to be “forward-looking statements” within the
federal securities laws, including the safe harbor provisions under
the Private Securities Litigation Reform Act of 1995. Statements
that are not historical are forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements relate to future events or our future performance or
future financial condition. These forward-looking statements are
not historical facts, but rather are based on current expectations,
estimates and projections about our company, our industry, our
beliefs and our assumptions. Such forward-looking statements
include, but are not limited to, statements regarding our or our
management team’s expectations, hopes, beliefs, intentions or
strategies regarding the future. In addition, any statements that
refer to projections, forecasts or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking statements. In some cases, you can
identify forward-looking statements by the following words:
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “ongoing,” “plan,” “potential,” “predict,”
“project,” “should,” or the negative of these terms or other
similar expressions, but the absence of these words does not mean
that a statement is not forward-looking. Forward-looking statements
are subject to a number of risks and uncertainties (some of which
are beyond our control) that may cause actual results or
performance to be materially different from those expressed or
implied by such forward-looking statements. Accordingly, readers
should not place undue reliance on any forward-looking statements.
These risks include risks relating to agreements with third
parties; our ability to raise funding in the future, as needed, and
the terms of such funding, including potential dilution caused
thereby; our ability to continue as a going concern; security
interests under certain of our credit arrangements; our ability to
maintain the listing of our common stock on the Nasdaq Capital
Market; claims relating to alleged violations of intellectual
property rights of others; risks that one or more conditions to
closing of the Merger may not be satisfied within the expected
timeframe or at all or that the closing of the proposed Merger will
not occur; the outcome of any current legal proceedings or future
legal proceedings that may be instituted against the parties or
others, including proceedings related to the Merger documents; the
occurrence of any event, change or other circumstance or condition
that could give rise to the termination or abandonment of the
Merger; unanticipated difficulties or expenditures relating to the
proposed Merger; potential difficulties in employee retention as a
result of the announcement and pendency of the proposed Merger;
whether the combined business of TRxADE and Superlatus will be
successful; and those risks detailed in TRxADE’s most recent Annual
Report on Form 10-K and subsequent reports filed with the
Securities and Exchange Commission. Forward-looking statements
speak only as of the date they are made. The TRxADE undertakes no
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise
that occur after that date, except as otherwise provided by
law.
Investor Contact:Skyline Corporate
Communications Group, LLCScott Powell, PresidentOne Rockefeller
Plaza, 11th FloorNew York, NY 10020Office: (646)
893-5835Email: info@skylineccg.com
TRxADE Health (NASDAQ:MEDS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
TRxADE Health (NASDAQ:MEDS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024